Cancer

Papers
(The H4-Index of Cancer is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Issue Information404
Sharp rise in esophageal cancer and Barrett esophagus seen in middle‐aged people263
Issue Information206
Stopping immunotherapy after 2 years is practical in patients with advanced non–small cell lung cancer202
Updated American Cancer Society lung cancer screening guidelines160
MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis160
Issue Information113
111
Cutaneous β‐HPV may predict cutaneous squamous cell carcinoma88
Issue Information82
New standard of care for multiple myeloma?81
77
Erratum to “Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation”73
New test for detecting cervical adenocarcinoma65
Accelerated approval of multiple myeloma therapies64
63
Cancer‐related impairments and functional limitations among long‐term cancer survivors: Gaps and opportunities for clinical practice58
Let's ask the patient: Self‐reported quality‐of‐life measures help to predict kidney cancer mortality56
Occurrence of breast‐cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two‐arm randomized clinical trial56
56
Active Living After Cancer: Adaptation and evaluation of a community‐based physical activity program for minority and medically underserved breast cancer survivors55
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia54
Evaluation of headache in patients with cancer53
Impact of TAILORx on chemotherapy prescribing and 21‐gene recurrence score–guided treatment costs in a population‐based cohort of patients with breast cancer51
Reply to “Empathic communication: The premise of inclusive care for historically excluded populations”51
Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)51
The economics of advanced and unresectable hepatocellular carcinoma50
Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing50
Understanding risk factors for cancer: What's new and how can it help reduce the cancer burden?50
Epistemic equity in oncology: Opportunities to leverage patient‐centric implementation in clinical trial design48
What enhanced recovery means for patients with cancer undergoing surgery48
Top advances of the year: Cervical cancer48
Potential of circulating tumor DNA to refine immunotherapy48
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?47
Aspirin but not statins is inversely related to gastric cancer with a duration–risk effect: Results from the Stomach Cancer Pooling Project Consortium47
Dietary supplement use among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study47
45
Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF144
Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data44
Association of high‐dose radiotherapy with improved survival in patients with newly diagnosed low‐grade gliomas43
What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?43
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders43
Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia42
Redefining the “crown”: Approaching chemotherapy‐induced alopecia among Black patients with breast cancer42
Effect of smoking reduction, cessation, and resumption on cancer risk: A nationwide cohort study42
0.077470064163208